# Longpan Investment

> Longpan Investment is a VC fund in Beijing backing Health Care and Medical. See 43 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Beijing, China
- Total investments: 43
- Last investment: Jul 2026
- Lead investor: 56%
- Last updated: Aug 2026

Longpan Investment is an investment firm.

## Contacts

5 contacts available for Longpan Investment. Shizune tracks 1 team members at Longpan Investment. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/longpan-investment?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $14M–$60M |
| Series A | $14M–$30M |
| Series B | $14M–$37M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 18 | 42% |
| Medical | 16 | 37% |
| Biotechnology | 16 | 37% |
| Biopharma | 9 | 21% |
| Pharmaceutical | 8 | 19% |

17 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 21 | 49% |
| Series B | 7 | 16% |
| Seed | 6 | 14% |
| Angel | 2 | 5% |
| Series C | 1 | 2% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 31 | 72% |
| United States | 1 | 2% |
| Cayman Islands | 1 | 2% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Wang Ji | Vice President | 3 | https://shizune.co/investors/profile/wang-ji |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Jingling Zhikang | Jingling Zhikang is technology company specializing in the intersection of medical rehabilitation, robotics, and embodied artificial intelligence. The company focuses on developing intelligent rehabilitation bionic hands and upper-limb prosthetics. | $14.8M | Angel | Jul 24, 2026 |  |
| Hanyue New Materials | Hanyue Advanced Materials is a high-tech company that specializes in single-use biopharmaceutical solutions. |  | Seed | Jul 02, 2026 |  |
| Lingtai Krypton Biotechnology | Lingtai Krypton Biotechnology is an innovative corporation that specializes in the development of lncRNA drugs. |  | Series A | Jun 26, 2026 |  |
| Qinghui Liannuo | Qinghui Liannuo is a scientific and technological innovation enterprise that transforms Tsinghua University's achievements in the research and development and application of immunotherapy technology. Actively promote the development of the γδ-T cell immunotherapy industry. Committed to bringing good news to patients with refractory andrecurrent solid tumors and hematomas. | $29.5M | Series A | Jun 09, 2026 |  |
| Bodie Hekang | Bodie Hekang is a biopharmaceutical services company dedicated to advancing therapies for autoimmune and inflammatory diseases. Combining translational research, preclinical development, and clinical support, the company specializes in engineering and developing regulatory T cell (Treg) immunotherapies designed to restore immune tolerance andreduce pathological inflammation. Bodie Hekang partners with academic institutions, biotech firms, and pharmaceutical companies to provide end-to-end services that include target validation, cell manufacturing process development, potency and safety testing, and regulatory strategy support. Its multidisciplinary team of immunologists, cell biologists, and clinical development experts focuses on innovative approaches to enhance Treg stability, specificity, and functionality, aiming to translate promising laboratory findings into scalable, clinically viable treatments for conditions such as rheumatoid arthritis, inflammatory bowel disease, and systemic lupus erythematosus. |  | Series A | May 21, 2026 |  |
| Maibozhixing | MaiboZhixing is an innovative company focused on antibody drug development and dedicated to developing next-generation antibody therapies for the treatment of inflammatory and autoimmune diseases. | $14.5M | Angel | Mar 23, 2026 |  |
| Baiyi Pharmaceutical | Baiyi Pharmaceutical is a research-driven pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for neurological diseases, aiming to address unmet medical needs and improve patient outcomes. | $14.3M | Seed | Jan 13, 2026 |  |
| Bohui Bio | Bohui Bio is an immune disease research and development company. | $14.2M | Series A | Dec 12, 2025 |  |
| Best-Link Bioscience | Best-Link Bioscience is a high-tech enterprise engaged in innovative drug research and development, focusing on cutting-edge scientific discovery, advanced therapeutic technologies, and the creation of novel medicines to address unmet clinical needs and improve patient outcomes worldwide. | $36.7M | Series B | Dec 11, 2025 |  |
| SynRx Therapeutics | Sanctuary Bio is a DNA damage repair drug developer, focusing on the field of DNA damage repair. | $14.1M | Series A | Dec 08, 2025 |  |

10 of 43 investments shown.

## Co-investors
- [Shanghai Biomedical Industrial Equity Investment Fund](https://shizune.co/investors/profile/shanghai-biomedical-industrial-equity-investment-fund) — VC Fund, 7 deals together
- [Delian Capital](https://shizune.co/investors/profile/delian-capital) — VC Fund, 4 deals together
- [Frees Fund](https://shizune.co/investors/profile/freesfund) — VC Fund, 3 deals together
- [RiverHead Capital](https://shizune.co/investors/profile/river-head-capital) — VC Fund, 3 deals together
- [Dingxin Capital](https://shizune.co/investors/profile/dingxin-capital) — VC Fund, 2 deals together
- [Highlight Capital](https://shizune.co/investors/profile/highlight-capital-llc) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [HSG](https://shizune.co/investors/profile/sequoia-capital-china) — VC Fund

## Featured in investor lists
- [Health Care Investors in China](https://shizune.co/investors/health-care-investors-china)
- [Health Care VC Funds in China](https://shizune.co/investors/health-care-vc-funds-china)
- [Health Care Investors in Asia](https://shizune.co/investors/health-care-investors-asia)
- [Health Care VC Funds in Asia](https://shizune.co/investors/health-care-vc-funds-asia)
- [Biotechnology VC Funds in China](https://shizune.co/investors/biotechnology-vc-funds-china)
- [Biotech VC Funds in China](https://shizune.co/investors/biotech-vc-funds-china)

## FAQ

### What does Longpan Investment invest in?

Longpan Investment invests primarily in Health Care, Medical and Biotechnology startups, most often at Series A and Series B stage. Most of the 43 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Longpan Investment's check size?

Longpan Investment typically joins rounds of $14M–$60M at Seed, $14M–$30M at Series A and $14M–$37M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Longpan Investment participates in.

### How do I contact Longpan Investment?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Longpan Investment?

The team at Longpan Investment includes Wang Ji (Vice President). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co